Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 7, 2011, Pages 1207-1212

  Sun, Yongliang ^a   Yang, Huayu ^a   Mao, Yilei ^a   Xu, Haifeng ^a   Zhang, Jinchun ^a   Li, Guangbing ^a   Lu, Xin ^a   Sang, Xinting ^a   Zhao, Haitao ^a   Zhong, Shouxian ^a   Huang, Jiefu ^a   Zhang, Hongbing ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Clinicopathologic correlation; Golgi protein 73; Hepatocellular carcinoma; Tumor progression

Indexed keywords

ALPHA FETOPROTEIN; GOLGI PROTEIN 73; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER HEMANGIOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 79958856366     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06733.x     Document Type: Article

References (23)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2: 533-43.
2. World Health Organization. Mortality Database. Cited 2009. Available from URL.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
4. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig. Dis. 2009; 27: 80-92.
5. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev. Gastroenterol. Hepatol. 2009; 3: 353-67.
6. Mao Y, Yang H, Xu H etal. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010; 59: 1687-93.
7. Mao Y, Yang H, Xu H etal. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Zhonghua Yi Xue Za Zhi (In Chinese with English Abstract) 2008; 88: 948-51.
8. Chen W, Yang H, Mao Y etal. GP73 monoclonal antibody in diagnosis of liver cancer. Acta Acad. Med. Sinicae (In Chinese with English Abstract) 2011; 33: 47-52.
9. Block TM, Comunale MA, Lowman M etal. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 779-84.
10. Marrero JA, Romano PR, Nikolaeva O etal. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J. Hepatol. 2005; 43: 1007-12.
11. Fimmel CJ, Wright L. Golgi protein 73 as a biomarker of hepatocellular cancer: development of a quantitative serum assay and expression studies in hepatic and extrahepatic malignancies. Hepatology 2009; 49: 1421-3.
12. Gu Y, Chen W, Zhao Y, Chen L, Peng T. Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann. Clin. Biochem. 2009; 46: 38-43.
13. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic 2007; 8: 1415-23.
14. Kladney RD, Bulla GA, Guo L etal. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000; 249: 53-65.
15. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002; 35: 1431-40.
16. Iftikhar R, Kladney RD, Havlioglu N etal. Disease- and cell-specific expression of GP73 in human liver disease. Am. J. Gastroenterol. 2004; 99: 1087-95.
17. Riener MO, Stenner F, Liewen H etal. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 2009; 49: 1602-9.
18. Schwegler EE, Cazares L, Steel LF etal. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41: 634-42.
19. Norton PA, Comunale MA, Krakover J etal. N-linked glycosylation of the liver cancer biomarker GP73. J. Cell. Biochem. 2008; 104: 136-49.
20. Maitra A, Thuluvath PJ. GP73 and liver disease: a (Golgi) complex enigma. Am. J. Gastroenterol. 2004; 99: 1096-8.
21. Lorinda MW, Sheri Y, Maria MP. Decreased survival and hepatorenal pathology in mice with C-terminally truncated GP73. Int. J. Clin. Exp. Pathol. 2009; 2: 34-47.
22. Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann. Surg. 2000; 232: 10-24.
23. Shimada K, Sano T, Sakamoto Y, Kosuge T. A long term follow-up and management study of hepatocellular carcinoma patients surviving for 10years or longer after curative hepatectomy. Cancer 2005; 104: 1939-47.